PepGen completes dosing in 15 mg/kg cohort of FREEDOM-DM1; net loss narrows to $23.1M

PepGen Inc.

2025-Q2 EPS reported -$1.63 vs consensus -$0.84 ▼ miss (-93.1%)

On track to report topline safety and splicing data from 15 mg/kg cohort in early Q4 2025.
Concluding FREEDOM trial after 15 mg/kg cohort; transitioning sites to Phase 2 MAD study FREEDOM2-DM1.
Cash $74.7M sufficient into Q2 2026; net loss $23.1M ($0.70/sh) vs $28.3M ($0.87/sh) YoY.
Appointed Kasra Kasraian, PhD, as Chief Technology Officer in May 2025.
FREEDOM2 5 mg/kg cohort results expected Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.